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Oncological hepatic resection: How does anyone know that it makes
a difference?
In this issue of HPB, Lim et al. on behalf of the e-HPBchir Study group provide a systematic review and critical analysis of
prognostic models for patients undergoing hepatic resection. The authors highlight the major deficiencies that currently
exist within the literature regarding the quality of available evidence that allows accurate identification of those patients who
will actually benefit from hepatic surgery. This issue is becoming increasingly pertinent as the indications for ‘curative
hepatic surgery’ have expanded over time due to increasing technical skills and the technological armamentarium available
to surgeons. These factors combined with increasing expectations of society with regard to health outcomes has led to an
explosion in the frequency with which hepatic resection is being conducted. Yet how do we know if this is making a
difference for the individual patient or population as a whole?
This question is becoming increasingly important for many health systems as the realisation that the continued
unchecked expansion of healthcare would appear to be financially unsustainable. Models that can accurately predict
outcomes based on cost effectiveness and quality of life will be required if rationalisation of healthcare is to be performed
in a fair and consistent manner.
As Lim et al. highlight, the currently available data suffer from several key deficiencies such as the variability of definitions,
poor statistical modelling and lack of meaningful endpoints. Simple examples include six definitions of peri-operative
mortality, eleven definitions for post-operative liver failure and lack of data regarding quality of life or cost effectiveness.
This article should provide food for thought for all hepatic surgeons regarding data collection. Crucially, it challenges
surgeons to reassess whether data points being collected are reproducible and useful, and to examine critically whether
outcome measures have been optimsied. Only once hepatic surgeons speak with a common language will the answer to
‘Should this patient undergo a hepatic resection?’ be able to be truly answered.
Saxon Connor
Swinging for the fences sometimes wins games
Minimal-change chronic pancreatitis (MCCP) is typically a full-gland, small duct variant of chronic pancreatitis (CP).
Because it leads to endocrine and exocrine pancreatic insufficiency (PI) together with chronic pain, it is a debilitating and
unremitting disease. Traditional management pivots on medical therapy for symptom control in hopes of gland burn-out
and eventual pain relief. Such an approach surrenders the victim however to PI. Wilson et al. from the University of
Cincinnati report on 84 patients over 10 years who underwent total pancreatectomy with islet cell autotransplantation
(TP/IAT) as an initial definitive therapy for MCCP. From technical standpoints, the patients endured safe operations with
acceptable morbidity rates and optimal islet yields, as would be expected of the Cincinnati team. As opposed to typical
male-predominant alcohol related CP, these patients were younger, usually female and had either genetic-mutation associ-
ated or idiopathic MCCP.While acknowledging the diagnostic shortcomings associated with MCCP, the authors detail and
emphasize a credible multidisciplinary model based on available evidence. The outcomes are quite compelling. With
follow-up subsets that extend beyond 5 years post TP/IAT, the study reveals impressive and sustained decreases in narcotic
requirements and stable glycaemic control. A full 37% enjoyed postoperative insulin independence. Patient quality of life
(QoL, SF-36) significantly improved early, but better, remained measurably improved longterm beyond the early postop-
erative period. These must be considered hallmark results and are derived from today’s largest study available that tests the
efficacy of aggressive TP/IAT for this mysterious disease. It compliments, but does not replace, other famous contributions
in the surgical management of chronic pancreatitis.
Mark Callery
Poor long-term outcomes from liver transplantation in the morbidly obese
Equity of access to transplantation is an important pillar of most solid organ transplant programmes. Standing opposite this
is the plain fact that not all recipients have as good outcomes as we might hope coupled with the undeniable limitation of
organs for transplantation. This lack of resource and desire for utility – the best outcome for these organs, creates a need for
rationing and patient selection and this in turn inevitably creates some conflict.
In this issue of HPB, Conzen and colleagues from Washington University look at outcomes of patients undergoing liver
transplantation based on recipient body mass index. The authors included all causes of chronic liver disease and higher
BMI’s were associated with higher rates of NAFLD as might be expected. High BMI patients had more hypertension but not
any other comorbidity compared with lower BMI groups.
Short-term outcomes were equivalent between lower and high BMI patients including operative timings and hospital
length of stay. Medium-term outcomes were also similar with non-significant differences in 90 day, 1 year and 3 year graft
and patient survivals. Longer term outcomes were a different story with patients with BMI > 40 having significantly worse
5 year (51% versus 79%) and 7 year (31% versus 72%) survival compared with lower BMI patients. Looking at the Kaplan
Meier curves it also appears that patients at the other end of the weight spectrum with a BMI < 18 also had a particularly
poor outcome but numbers were small.
NAFLD is a growing indication for liver transplantation and this manuscript recommends aggressive management of the
metabolic syndrome. It does stop short of recommending limiting access to liver transplantation for the BMI > 40 individuals
but perhaps these and other data provide justification for considering some limits for transplant eligibility based on BMI.
Stephen J Wigmore
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